Pipeline of launches: Creso Pharma Limited (ASX: CPH) reported that they are on track to launch their CannaQix human health nutraceutical product in anxiety and stress segment by first quarter or second quarter of 2018. They are also aiming and line extensions in bone metabolism by second quarter of 2019. The products use proprietary Swiss delivery technologies which would boost the bioavailability and absorption of their active ingredients. In May, importation of medicinal cannabis in Australia happened while the first patients are currently getting CanniMed oils via Creso’s partner, Health House International. Creso Pharma is targeting to import medical cannabis products into the Asia-Pacific and Latin American regions from Switzerland, post their deal with Cannapharm AG. Meanwhile, Creso Pharma is aiming to launch several SwissVit premium nutraceutical products across the Asia-Pacific region and Australia. These premium, high-quality nutraceutical products are collaborated with INNutriGEL Switzerland using the INNutriGEL SoftGums proprietary delivery technology that was specifically formulated for that range. SoftGums are made from vegetable starch, and not animal waste material like current gelatinbased vitamin competitor supplements on the market.